Partner Article

Boldon’s IDS looks to the future after revealing anticipated revenue decline

Immunodiagnostic Systems Holdings plc, a producer of manual and automated specialist diagnostic testing kits and instrumentation for clinical and research markets, has today confirmed an anticipated decline in revenue.

Revealing its final results for the year ended 31 March 2015, the Boldon-based drug testing company announced a 13.2% decrease in revenues, as first highlighted in a May trading update, falling from £52.3m to £45.4m.

In addition, the company saw pretax profits fall from £8.335m last year to £4.053m, a drop of almost £4.3m.

IDS will now pursue a strategic plan based around four main areas as it looks to build a sustainable, profitable future.

Patricio Lacalle, CEO of IDS, said: “We are committed to implementing our strategic priorities, namely; increased automated assay menu; increased net new placements; cost management and M&A.

“The current financial year will be one of transition for IDS as we look to build a solid sustainable platform for the future.”

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.